Value-Based Care

CVAUSA and InnovaCare’s Value-Based Alliance

Transitioning to value-based care is at the center of most private equity cardiology groups’ strategies, and a recently-announced alliance between Cardiovascular Associates of America (CVAUSA) and InnovaCare Health is aiming to create a new model for cardiology + primary care VBC delivery.

The alliance involves three key stakeholders…

  • InnovaCare Health – Florida-based integrated care provider with a big focus on VBC
  • Family Care Partners – Jacksonville-based primary care physician group, owned by InnovaCare
  • First Coast Heart and Vascular Centers – Jacksonville-based cardiology group, owned by CVAUSA

The three groups will focus on “improving care quality and reducing total costs” for Family Care Partners’ patients through…

  • More proactive and efficient management of chronic cardiovascular diseases 
  • Improving access to timely cardiovascular care
  • Improving co-management of shared patients
  • And hopefully reducing hospitalizations and emergency room visits, and shifting care to the “lowest cost sites”

Although this is a “first-of-its-kind” alliance in cardiology, some might have seen it coming given the massive costs associated with low-value cardiovascular care, the benefits of improving cardiology/primary care collaboration, and the emphasis CVAUSA has placed on VBC. 

  • In fact, this alliance is directly tied to CVAUSA’s acquisition of VBC-focused cardiology practice NovoCardia in April, noting that NovoCardia now appears to be spearheading its VBC strategy and First Coast Heart and Vascular was previously one of NovoCardia’s practices.

The Takeaway

Over $320B is spent on cardiovascular care in the US each year, leaving plenty of room for low-value care, and plenty of opportunities for improvements through VBC alliances like this.

Whether CVAUSA and InnovaCare significantly improve value at Family Care Partners remains to be seen, but at least for now CVUSA believes that this partnership will become a model for how cardiovascular and primary care-focused VBC alliances can operate.

If it does prove successful, CVAUSA and InnovaCare have plenty of other Florida practices to expand to.

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Atrial Fibrillation November 10, 2025

ARREST-AF and the Importance of Lifestyle Post-Ablation November 10, 2025

Catheter ablation for atrial fibrillation might be missing half its potential, after results from the ARREST-AF trial demonstrated that structured lifestyle and risk factor management significantly increases a patient’s 12-month freedom from arrhythmia while cutting recurrence risk nearly in half. That could be changing now, thanks to the ARREST-AF trial which randomized 122 patients with […]

Heart Failure November 6, 2025

PREVENT-TAHA8 Supports Stem Cells for Post-MI HF November 6, 2025

Stem cell therapy for post-MI heart failure might deserve a second look, after the PREVENT-TAHA8 trial demonstrated that mesenchymal stem cell infusion within days of STEMI significantly reduced 3-year HF incidence. Based in Iran, the PREVENT-TAHA8 trial, randomized 396 patients following LAD STEMI with LVEF <40%, to receive either an intracoronary mesenchymal stem cell infusion […]

Structural Heart November 3, 2025

Abbott’s Tendyne TMVR System Works Even in the Sickest MR Patients November 3, 2025

New research presented at TCT 2025 suggests that Abbott’s FDA-approved Tendyne TMVR system leads to significantly better health outcomes in patients with severe mitral annular calcification who were previously considered untreatable. The SUMMIT-MAC trial enrolled 103 patients with severe MAC and found that the challenging patient population showed strong outcomes despite extreme pathology… However, patients […]